Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Last trade$0.202
Day change-$0.0078 (-3.72%)
Day range$0.201 – $0.228
Volume324,045
Market cap$29M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$29.46M
Price / earnings
—
Price / book
0.74×
Price / sales
0.27×
EV / sales
0.39×
EV / EBITDA
-28.93×
Profitability
Earnings per share
-$0.08
Return on assets
-13.98%
Return on equity
-27.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.58×
Current ratio
2.16×
Quick ratio
1.05×
Cash ratio
0.33×
Cash flow
Price / cash flow
51.69×
Price / free cash flow
—
Free cash flow
-$696K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XTNT, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$23.03M
$20.88M
$32.36M
$33.26M
$35.41M
$32.9M
$31.51M
$27.94M
Cost of revenue
$9.7M
$8.91M
$14.6M
$11.26M
$11.13M
$12.66M
$15.49M
$11.63M
Gross profit
$13.33M
$11.97M
$17.75M
$21.99M
$24.28M
$20.24M
$16.02M
$16.31M
Selling, general and administrative
$16.8M
$14.46M
$18.24M
$18.82M
$19.09M
$18.74M
$17.38M
$19.38M
Research and development
$695K
$435K
$459K
$634K
$566K
$443K
$522K
$701K
Total operating expenses
$22.5M
$14.89M
$18.7M
$19.45M
$19.66M
$19.18M
$17.91M
$20.08M
Operating income
-$9.17M
-$2.92M
-$944K
$2.54M
$4.62M
$1.06M
-$1.88M
-$3.78M
Interest expense
-$542K
-$599K
-$718K
-$904K
-$1M
-$1.05M
-$1.13M
-$1.2M
Income before taxes
-$9.34M
-$3.06M
$1.6M
$1.57M
$3.81M
$33K
-$3.14M
-$4.96M
Income taxes
$73K
$27K
$1.54M
$257K
$255K
-$25K
$21K
$62K
Net income
-$9.41M
-$3.09M
$57K
$1.31M
$3.55M
$58K
-$3.17M
-$5.02M
Net income attributable to common shareholders
-$9.41M
-$3.09M
$57K
$1.31M
$3.55M
$58K
-$3.17M
-$5.02M
EBITDA
-$3.66M
-$2.39M
$875K
$3.7M
$5.79M
$2.14M
-$734K
-$2.7M
Basic earnings per share
-$0.07
-$0.02
$0.00
$0.01
$0.03
$0.00
-$0.02
-$0.04
Diluted earnings per share
-$0.07
-$0.02
$0.00
$0.01
$0.02
$0.00
-$0.02
-$0.04
Recent news
Company coverage with links to the original publishers.
BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™.
BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024.
BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company’s term loan was also amended to provide for an additional $10.0 million tranche, to be made available for acquisitions at MidCap’s discretion. The maturity dates of Xtant’s revolving credit facility and term loan were extended to March 1, 2029 and minimum net product revenue requirements specified in the agreements were reset and minimum Adjusted EBITDA requirements were removed. Additionally, the applicable margin used to determine the per annum interest rate of the term loan was reduced from 7.00% to 6.50%.
BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.